# Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

> **NCT07166081** · PHASE1 · RECRUITING · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Non-diabetic Overweight or Obese

## Interventions

- **DRUG:** BGM0504
- **DRUG:** BGM0504
- **DRUG:** BGM0504
- **DRUG:** Placebo
- **DRUG:** BGM0504

## Key facts

- **NCT ID:** NCT07166081
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-05-13
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166081, "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07166081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*